<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785875</url>
  </required_header>
  <id_info>
    <org_study_id>20120231</org_study_id>
    <secondary_id>KAI-4169-008</secondary_id>
    <secondary_id>2012-002808-41</secondary_id>
    <nct_id>NCT01785875</nct_id>
  </id_info>
  <brief_title>Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis</brief_title>
  <official_title>A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to describe the long-term safety and efficacy of etelcalcetide (AMG
      416) for the treatment of SHPT in adults with CKD on hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first dose until 30 days after last dose; the treatment period was 52 weeks.</time_frame>
    <description>Treatment-related adverse events are those the investigator indicated as having a reasonable possibility of having been caused by etelcalcetide. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4</measure>
    <time_frame>52 weeks</time_frame>
    <description>Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 0 represents values in the normal range and grade 4 represents values with life-threatening consequences and urgent intervention indicated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Developed Anti-etelcalcetide Antibodies</measure>
    <time_frame>Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit</time_frame>
    <description>A validated dual flow-cell biosensor immunoassay was used to detect antibodies capable of binding etelcalcetide. The number of participants with a negative or no result at baseline and positive binding antibodies at any time post-baseline is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline and Weeks 24 and 48</time_frame>
    <description>Blood pressure (BP) values were taken post-hemodialysis assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt; 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase</measure>
    <time_frame>Baseline and the efficacy assessment phase, defined as the last 6 weeks prior to ending treatment for participants who completed a minimum of 8 weeks of treatment (weeks 46-52 for participants who completed 52 weeks of treatment)</time_frame>
    <description>The efficacy assessment phase (EAP) is defined as the last 6 weeks before ending treatment, which was only for participants who completed a minimum of 8 weeks of treatment with etelcalcetide. If multiple assessments were available during the EAP, values were averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt; 30% Reduction From Baseline in PTH During the EAP12</measure>
    <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
    <description>The efficacy assessment phase at 12 months (EAP12) was defined as the period from week 46 to 53 (inclusive). If multiple assessments were available during the EAP12, values were averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PTH ≤ 300 pg/mL During the EAP</measure>
    <time_frame>Baseline and the efficacy assessment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12</measure>
    <time_frame>Week 46 to 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean PTH During the EAP</measure>
    <time_frame>Baseline and the efficacy assessment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean PTH During the EAP12</measure>
    <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Corrected Calcium During the EAP</measure>
    <time_frame>Baseline and the efficacy assessment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Corrected Calcium During the EAP12</measure>
    <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP</measure>
    <time_frame>Baseline and the efficacy assessment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12</measure>
    <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Phosphorus During the EAP</measure>
    <time_frame>Baseline and the efficacy assessment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Phosphorus During the EAP12</measure>
    <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">891</enrollment>
  <condition>Hyperparathyroidism, Secondary</condition>
  <arm_group>
    <arm_group_label>Etelcalcetide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etelcalcetide</intervention_name>
    <description>Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).</description>
    <arm_group_label>Etelcalcetide</arm_group_label>
    <other_name>AMG 416</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject understands the study procedures and agrees to participate in the study by
             giving written informed consent.

          -  Subject must complete the treatment and follow-up period, or have been discontinued
             for rising intact parathyroid hormone (iPTH), from an AMG 416 phase 3 parent study
             prior to the start of dosing in this study: 20120229 (NCT01785849), 20120230
             (NCT01788046), or 20120359 (NCT01932970).

          -  Subject agrees to not participate in another study of an investigational agent during
             the study.

          -  Other Inclusion Criteria may apply

        Exclusion Criteria:

          -  Currently receiving treatment in another investigational device or drug study.

          -  Currently receiving other investigational procedures while participating in this
             study.

          -  Subject has known sensitivity to any of the products or components to be administered
             during dosing.

          -  Subject has an unstable medical condition based on medical history, physical
             examination, and routine laboratory tests, or is otherwise unstable in the judgment of
             the Investigator.

        Other Exclusion Criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cudahy</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <zip>94534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Gabriel</city>
        <state>California</state>
        <zip>91776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pinecrest</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merrillville</city>
        <state>Indiana</state>
        <zip>46410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-2998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brookhaven</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New York</state>
        <zip>11385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yonkers</city>
        <state>New York</state>
        <zip>10704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carrboro</city>
        <state>North Carolina</state>
        <zip>27510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Prairie</city>
        <state>Texas</state>
        <zip>75050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mansfield</city>
        <state>Texas</state>
        <zip>76063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bluefield</city>
        <state>West Virginia</state>
        <zip>24701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4 - Nusle</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 6</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slavkov u Brna</city>
        <zip>684 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Tronche cedex</city>
        <zip>38701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13253</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Ouen</city>
        <zip>93400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1037</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <zip>60131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Enschede</city>
        <zip>7511 JX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Golub-Dobrzyn</city>
        <zip>87-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamosc</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123183</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198510</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucía</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>February 7, 2017</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <disposition_first_submitted>December 19, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 19, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 25, 2016</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This single-arm study was conducted at 205 centers in the US, Canada, Europe, Israel, Russian Federation and Australia. Participants were enrolled from 31 July 2013 to 9 June 2014.
Participants who rolled over into another single-arm extension study 20130213 (NCT02102204) are reported as discontinuing the study due to protocol specified criteria.</recruitment_details>
      <pre_assignment_details>This extension study enrolled participants from 1 of 3 parent studies: 20120229 (NCT01785849), 20120230 (NCT01788046), or 20120359 (NCT01932970). In Studies 20120229 and 20120230, patients received either placebo or etelcalcetide 3 times a week (TIW) for up to 26 weeks; In Study 20120359, patients received 5 mg etelcalcetide TIW for 4 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>20120229 / 20120230 Placebo</title>
          <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
        <group group_id="P2">
          <title>20120229 / 20120230 Etelcalcetide</title>
          <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
        <group group_id="P3">
          <title>20120359 Etelcalcetide</title>
          <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="384"/>
                <participants group_id="P3" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Etelcalcetide</title>
              <participants_list>
                <participants group_id="P1" count="383"/>
                <participants group_id="P2" count="384"/>
                <participants group_id="P3" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90">Completed etelcalcetide and the 30-day safety follow-up period</participants>
                <participants group_id="P2" count="95">Completed etelcalcetide and the 30-day safety follow-up period</participants>
                <participants group_id="P3" count="16">Completed etelcalcetide and the 30-day safety follow-up period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="214"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etelcalcetide</title>
          <description>All participants received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks during the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="891"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (or African American)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parathyroid Hormone (PTH) Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 600 pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>600 - ≤ 1000 pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 1000 pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTH Concentration</title>
          <description>Data available for 854 participants</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="769.5" spread="574.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrected Calcium</title>
          <description>Data available for 889 participants</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.67" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Phosphorus</title>
          <description>Data available for 887 participants</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.63" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrected Calcium Phosphorus Product (cCa x P)</title>
          <description>Data available for 887 participants</description>
          <units>mg²/dL²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.36" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>Treatment-related adverse events are those the investigator indicated as having a reasonable possibility of having been caused by etelcalcetide. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event.</description>
        <time_frame>From first dose until 30 days after last dose; the treatment period was 52 weeks.</time_frame>
        <population>All participants who received at least 1 dose of etelcalcetide.</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>Treatment-related adverse events are those the investigator indicated as having a reasonable possibility of having been caused by etelcalcetide. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event.</description>
          <population>All participants who received at least 1 dose of etelcalcetide.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="384"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="337"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation of etelcalcetide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4</title>
        <description>Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 0 represents values in the normal range and grade 4 represents values with life-threatening consequences and urgent intervention indicated.</description>
        <time_frame>52 weeks</time_frame>
        <population>All participants who received at least 1 dose of etelcalcetide.</population>
        <group_list>
          <group group_id="O1">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4</title>
          <description>Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 0 represents values in the normal range and grade 4 represents values with life-threatening consequences and urgent intervention indicated.</description>
          <population>All participants who received at least 1 dose of etelcalcetide.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (corrected) decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (corrected) increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Anti-etelcalcetide Antibodies</title>
        <description>A validated dual flow-cell biosensor immunoassay was used to detect antibodies capable of binding etelcalcetide. The number of participants with a negative or no result at baseline and positive binding antibodies at any time post-baseline is reported.</description>
        <time_frame>Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit</time_frame>
        <population>Participants who received at least 1 dose of etelcalcetide and with a post-baseline antibody result.</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-etelcalcetide Antibodies</title>
          <description>A validated dual flow-cell biosensor immunoassay was used to detect antibodies capable of binding etelcalcetide. The number of participants with a negative or no result at baseline and positive binding antibodies at any time post-baseline is reported.</description>
          <population>Participants who received at least 1 dose of etelcalcetide and with a post-baseline antibody result.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="384"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With &gt; 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase</title>
        <description>The efficacy assessment phase (EAP) is defined as the last 6 weeks before ending treatment, which was only for participants who completed a minimum of 8 weeks of treatment with etelcalcetide. If multiple assessments were available during the EAP, values were averaged.</description>
        <time_frame>Baseline and the efficacy assessment phase, defined as the last 6 weeks prior to ending treatment for participants who completed a minimum of 8 weeks of treatment (weeks 46-52 for participants who completed 52 weeks of treatment)</time_frame>
        <population>Participants with pre-dialysis PTH assessment at baseline and during the EAP who completed a minimum of 8 weeks of treatment with etelcalcetide.</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt; 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase</title>
          <description>The efficacy assessment phase (EAP) is defined as the last 6 weeks before ending treatment, which was only for participants who completed a minimum of 8 weeks of treatment with etelcalcetide. If multiple assessments were available during the EAP, values were averaged.</description>
          <population>Participants with pre-dialysis PTH assessment at baseline and during the EAP who completed a minimum of 8 weeks of treatment with etelcalcetide.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="332"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="779"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="76.7" upper_limit="85.2"/>
                    <measurement group_id="O2" value="54.5" lower_limit="49.0" upper_limit="60.0"/>
                    <measurement group_id="O3" value="65.1" lower_limit="55.2" upper_limit="74.1"/>
                    <measurement group_id="O4" value="67.7" lower_limit="64.2" upper_limit="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With &gt; 30% Reduction From Baseline in PTH During the EAP12</title>
        <description>The efficacy assessment phase at 12 months (EAP12) was defined as the period from week 46 to 53 (inclusive). If multiple assessments were available during the EAP12, values were averaged.</description>
        <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
        <population>Participants with pre-dialysis PTH assessment at baseline and during EAP12</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt; 30% Reduction From Baseline in PTH During the EAP12</title>
          <description>The efficacy assessment phase at 12 months (EAP12) was defined as the period from week 46 to 53 (inclusive). If multiple assessments were available during the EAP12, values were averaged.</description>
          <population>Participants with pre-dialysis PTH assessment at baseline and during EAP12</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="77.7" upper_limit="86.6"/>
                    <measurement group_id="O2" value="53.3" lower_limit="47.5" upper_limit="59.1"/>
                    <measurement group_id="O3" value="63.5" lower_limit="51.5" upper_limit="74.4"/>
                    <measurement group_id="O4" value="67.5" lower_limit="63.8" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PTH ≤ 300 pg/mL During the EAP</title>
        <time_frame>Baseline and the efficacy assessment phase</time_frame>
        <population>Participants with predialysis PTH assessment during the EAP who completed a minimum of 8 weeks of treatment with etelcalcetide</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PTH ≤ 300 pg/mL During the EAP</title>
          <population>Participants with predialysis PTH assessment during the EAP who completed a minimum of 8 weeks of treatment with etelcalcetide</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="355"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="815"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" lower_limit="50.3" upper_limit="60.9"/>
                    <measurement group_id="O2" value="59.7" lower_limit="54.4" upper_limit="64.9"/>
                    <measurement group_id="O3" value="54.6" lower_limit="44.8" upper_limit="64.2"/>
                    <measurement group_id="O4" value="57.3" lower_limit="53.8" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12</title>
        <time_frame>Week 46 to 53</time_frame>
        <population>Participants with predialysis PTH assessment during the EAP12</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12</title>
          <population>Participants with predialysis PTH assessment during the EAP12</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="321"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="708"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="49.1" upper_limit="60.4"/>
                    <measurement group_id="O2" value="61.1" lower_limit="55.5" upper_limit="66.4"/>
                    <measurement group_id="O3" value="42.7" lower_limit="31.3" upper_limit="54.6"/>
                    <measurement group_id="O4" value="56.4" lower_limit="52.6" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean PTH During the EAP</title>
        <time_frame>Baseline and the efficacy assessment phase</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean PTH During the EAP</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="332"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="779"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.55" spread="2.12"/>
                    <measurement group_id="O2" value="3.92" spread="8.68"/>
                    <measurement group_id="O3" value="-28.40" spread="6.96"/>
                    <measurement group_id="O4" value="-26.07" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean PTH During the EAP12</title>
        <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean PTH During the EAP12</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="676"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.41" spread="2.20"/>
                    <measurement group_id="O2" value="4.78" spread="9.62"/>
                    <measurement group_id="O3" value="-27.05" spread="7.57"/>
                    <measurement group_id="O4" value="-25.59" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Corrected Calcium During the EAP</title>
        <time_frame>Baseline and the efficacy assessment phase</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Corrected Calcium During the EAP</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="352"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.01" spread="0.52"/>
                    <measurement group_id="O2" value="-6.74" spread="0.47"/>
                    <measurement group_id="O3" value="-8.65" spread="1.04"/>
                    <measurement group_id="O4" value="-8.41" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Corrected Calcium During the EAP12</title>
        <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Corrected Calcium During the EAP12</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.76" spread="0.52"/>
                    <measurement group_id="O2" value="-6.43" spread="0.45"/>
                    <measurement group_id="O3" value="-9.73" spread="1.14"/>
                    <measurement group_id="O4" value="-8.25" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP</title>
        <time_frame>Baseline and the efficacy assessment phase</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="345"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.26" spread="1.58"/>
                    <measurement group_id="O2" value="-10.41" spread="1.61"/>
                    <measurement group_id="O3" value="-6.58" spread="4.28"/>
                    <measurement group_id="O4" value="-12.04" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12</title>
        <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.30" spread="1.53"/>
                    <measurement group_id="O2" value="-9.78" spread="1.62"/>
                    <measurement group_id="O3" value="-7.29" spread="4.82"/>
                    <measurement group_id="O4" value="-11.95" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Phosphorus During the EAP</title>
        <time_frame>Baseline and the efficacy assessment phase</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Phosphorus During the EAP</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.71" spread="1.71"/>
                    <measurement group_id="O2" value="-3.50" spread="1.68"/>
                    <measurement group_id="O3" value="2.82" spread="4.56"/>
                    <measurement group_id="O4" value="-3.62" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Phosphorus During the EAP12</title>
        <time_frame>Baseline and the efficacy assessment phase at month 12 (weeks 46-53)</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Phosphorus During the EAP12</title>
          <population>Participants with available data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="703"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.87" spread="1.65"/>
                    <measurement group_id="O2" value="-3.06" spread="1.73"/>
                    <measurement group_id="O3" value="3.53" spread="5.46"/>
                    <measurement group_id="O4" value="-3.59" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure</title>
        <description>Blood pressure (BP) values were taken post-hemodialysis assessments.</description>
        <time_frame>Baseline and Weeks 24 and 48</time_frame>
        <population>Participants who received at least 1 dose of etelcalcetide and with available data at each time point (indicated by n)</population>
        <group_list>
          <group group_id="O1">
            <title>20120229 / 20120230 Placebo</title>
            <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O2">
            <title>20120229 / 20120230 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O3">
            <title>20120359 Etelcalcetide</title>
            <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
          <group group_id="O4">
            <title>Etelcalcetide Total</title>
            <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure</title>
          <description>Blood pressure (BP) values were taken post-hemodialysis assessments.</description>
          <population>Participants who received at least 1 dose of etelcalcetide and with available data at each time point (indicated by n)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="384"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP Week 24 (n = 329, 342, 104, 775)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.5"/>
                    <measurement group_id="O2" value="4.5" spread="1.4"/>
                    <measurement group_id="O3" value="-5.5" spread="2.8"/>
                    <measurement group_id="O4" value="2.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP Week 48 (n = 305, 317, 74, 696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.6"/>
                    <measurement group_id="O2" value="6.5" spread="1.5"/>
                    <measurement group_id="O3" value="-6.8" spread="3.0"/>
                    <measurement group_id="O4" value="3.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP Week 24 (n = 329, 343, 104, 776)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.8"/>
                    <measurement group_id="O2" value="1.2" spread="0.9"/>
                    <measurement group_id="O3" value="-5.1" spread="1.5"/>
                    <measurement group_id="O4" value="0.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP Week 48 (n = 305, 317, 74, 696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.9"/>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                    <measurement group_id="O3" value="-2.6" spread="1.7"/>
                    <measurement group_id="O4" value="0.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose until 30 days after last dose; the treatment period was 52 weeks.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>20120229 / 20120230 Placebo</title>
          <description>Participants who received placebo in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
        <group group_id="E2">
          <title>20120229 / 20120230 Etelcalcetide</title>
          <description>Participants who received etelcalcetide in parent study 20120229 or 20120230 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
        <group group_id="E3">
          <title>20120359 Etelcalcetide</title>
          <description>Participants who received etelcalcetide in parent study 20120359 received etelcalcetide at a starting dose of 5 mg TIW for up to 52 weeks in the extension study. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
          <description>Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="356" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Anorectal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastrointestinal vascular malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pancreatic duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Drug resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hyperthermia malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bacterial tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Genital abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Coronary bypass thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dialysis related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemodialysis-induced symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Stoma site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hepatitis C antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Colon cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pelvic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vasculitic rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="613" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="385" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="890"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="890"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

